Related Experiment Video
Updated: Jan 30, 2026
Using Chronic Social Stress to Model Postpartum Depression in Lactating Rodents
Published on: June 10, 2013
Prophylactic esketamine to reduce postpartum depression in primiparae: A multicentre, double-blind, randomised
Tiantian Chu1, Xiaoling Peng, Keliang Wan
1From the Department of Anaesthesiology, Hubei Key Laboratory of Geriatric Anaesthesia and Peri-operative Brain Health, and Wuhan Clinical Research Centre for Geriatric Anaesthesia, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan (TC, XP, KW, ML, TL, XS, WY, SL, ZZ, AL, AX, FG), Department of Anaesthesiology, Jingmen Central Hospital affiliated to Jingchu University of Technology, Jingmen (CY, JK, CW), Department of Anaesthesiology, Maternal and Child Health Hospital of Hubei Province, Wuhan (HX, JC, ZX), Department of Anaesthesiology, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou (DL), Department of Anaesthesiology, the People's Hospital of Hanchuan, Hanchuan (XL), Department of Anaesthesiology, the People's Hospital of Jingmen, Jingmen (JH) and Department of Anaesthesiology & Institute of Neuroscience and Brain Diseases, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China (XY).
Background:
Postpartum depression (PPD) is a common complication after childbirth, especially in primiparae.
Objectives:
This trial sought to evaluate whether prophylactic administration of esketamine during the perinatal period could prevent PPD in primiparae without predisposition to prenatal depression.
Design:
A prospective, double-blind, multicentre, randomised controlled trial.
Setting:
Three academic hospitals.
Patients:
Primiparae scheduled for elective caesarean section with an Edinburgh Postnatal Depression Scale (EPDS) score less than 10.
Interventions:
Postnatal women were randomly assigned to receive either i.v. esketamine in a single dose of 0.25 mg kg -1 followed by 80 mg of esketamine as an adjunct to 24-h patient-controlled intravenous analgesia (PCIA). Women in the control group received an equal volume of saline.
Main Outcome Measures:
The primary outcome was the total incidence of PPD within 3 months postpartum. Secondary outcomes included postoperative EPDS scores, numeric rating scale scores, sufentanil consumption, the number of effective presses for postoperative intravenous analgesia and adverse events.
Results:
A total of 322 patients were included in the modified intention-to-treat analysis. The total incidence of PPD in the esketamine group (11.59%) was significantly less than the control group (20.89%) [adjusted relative ratio (RR), 0.57; 95% CI, 0.35 to 0.94; P = 0.028] as was the incidence at 7 days postpartum (4.89 vs. 15.19%; adjusted RR, 0.32; 95% CI, 0.15 to 0.72; P = 0.005). However, there were no significant differences in PPD incidence and EPDS scores at 1, 2 and 3 months postpartum, respectively. Several mild central nervous events, such as dizziness (10.98%), hallucination (10.37%) and dissociation (5.49%), were observed during esketamine treatment.
Conclusion:
Peri-operative adjunctive administration of esketamine is relatively safe and can prevent PPD in primi-parae without predisposition to prenatal depression in the short term.
Trial Registration:
Clinicaltrials.gov. Identifier: NCT04860661.
Related Concept Videos
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
02:07Blind Procedures
01:12Statistical Software for Data Analysis and Clinical Trials
01:11Blinding
01:05Long-term Depression